{"product_id":"collegiumpharma-five-forces-analysis","title":"Collegium Pharmaceutical Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical faces nuanced competitive pressures across supplier leverage, buyer power, regulatory barriers, and substitute threats that shape its strategic outlook. This snapshot highlights key tensions but omits force-by-force ratings, visuals, and implications. Unlock the full Porter's Five Forces Analysis to get a consultant-grade, actionable breakdown tailored to Collegium Pharmaceutical.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eControlled-substance API constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOpioid APIs are subject to DEA annual aggregate production quotas and specialized compliance controls, which in 2024 remained the primary regulatory limit on Schedule II API supply and restrict the pool of qualified suppliers. Any quota cuts or a single compliant supplier disruption can materially constrain production and inventory, creating outsized leverage for those manufacturers. Collegium must maintain strict chain-of-custody, DEA auditing and vendor qualification programs, raising switching costs and concentrating bargaining power with compliant API producers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized ADF components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbuse-deterrent formulation inputs and know-how are highly niche, exemplified by Collegium's DETERx-based Xtampza ER remaining its flagship ADF product as of 2024, which narrows qualified vendor options. Proprietary excipients and specialized processing equipment are not easily substitutable, and qualification and tech-transfer timelines commonly exceed 12 months, further entrenching suppliers. This dynamic elevates dependence on a few specialized partners.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCMO and packaging reliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium relies on outsourced CMOs and specialized controlled-substance packagers that must be fully validated, so capacity constraints or quality lapses can halt supply chains and prompt recalls. Dual-sourcing is feasible but in regulated settings adds significant validation time and cost, limiting rapid switches. These vendors therefore gain negotiating leverage over timelines, pricing, and contract terms, raising supplier power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality and regulatory switching costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGMP, serialization, and validation requirements make supplier changes slow and costly for Collegium; as of 2024 FDA enforcement continued to emphasize GMP compliance, so material supplier shifts trigger regulatory filing updates and lengthy revalidation. The risk of FDA observations and prolonged remediation drives firms to prioritize supplier stability over renegotiation, structurally increasing supplier bargaining power.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGMP\/serialization\/validation =\u0026gt; high switching costs\u003c\/li\u003e\n\u003cli\u003eRegulatory filings must be updated after supplier changes\u003c\/li\u003e\n\u003cli\u003eFDA observation risk favors stability\u003c\/li\u003e\n\u003cli\u003eNet effect: stronger supplier power\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMitigants via scale and contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLong-term agreements, safety stocks and second-source qualifications materially reduce supply disruption risk for Collegium by locking pricing and ensuring continuity, while broader excipient markets keep non-specialty input prices competitive. Performance-based SLAs align incentives and quality with key contract manufacturers; collectively these levers partially offset concentrated supplier power.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLong-term agreements\u003c\/li\u003e\n\u003cli\u003eSafety stocks\u003c\/li\u003e\n\u003cli\u003eSecond-source qualifications\u003c\/li\u003e\n\u003cli\u003ePerformance-based SLAs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDEA quotas concentrate Schedule II API supply; qualification \u0026gt; \u003cstrong\u003e12 months\u003c\/strong\u003e raises switching costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDEA annual aggregate production quotas remained the primary limit on Schedule II API supply in 2024, concentrating qualified suppliers and raising their leverage. Qualification and tech-transfer timelines commonly exceed 12 months, keeping switching costs high. Outsourced CMOs and controlled-substance packagers are capacity-constrained and require lengthy revalidation, elevating supplier bargaining power.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDEA quota impact\u003c\/td\u003e\n\u003ctd\u003ePrimary limiter\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualification time\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching costs\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter’s Five Forces analysis tailored to Collegium Pharmaceutical that evaluates competitive rivalry, supplier and buyer power, threat of substitutes, and barriers to entry to illuminate pricing pressure and profitability drivers. Highlights disruptive therapies, regulatory and IP barriers, and market dynamics shaping Collegium’s strategic positioning and growth risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, one-sheet Porter’s Five Forces summary tailored to Collegium Pharmaceutical that highlights competitive pressures and regulatory risk—perfect for quick strategic decisions. Easily customize force ratings and swap scenarios to relieve analysis bottlenecks and feed boardroom decks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBM and payer formulary control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge PBMs and insurers—CVS Caremark, Express Scripts and OptumRx—control roughly 78–80% of U.S. commercial prescription routing, dictating coverage, tiers and prior authorizations. They extract rebates often in the high double-digits (commonly \u0026gt;30%) and impose step therapy, pressuring Collegium’s net pricing. Formulary exclusions or unfavorable tiering can materially cut market access and volumes. Ongoing PBM consolidation amplifies this bargaining power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale and GPO concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDistributors and GPOs aggregate demand across pharmacies and hospitals, with the top three wholesalers (McKesson, Cardinal, AmerisourceBergen) accounting for roughly 85% of U.S. pharmaceutical distribution in 2024, giving them outsized leverage over Collegium. Their use of chargebacks and service fees—often structured as retroactive rebates and billing adjustments—compresses manufacturer margins. Failure to meet strict service metrics risks delisting, fines or reduced contract access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapeutic interchangeability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOpioids and non-opioid analgesics give prescribers multiple options, and U.S. opioid prescriptions have fallen roughly 50% since their peak, increasing substitution pressure. Buyers leverage alternatives to extract price concessions and formulary placement, forcing manufacturers to compete on net price. Abuse-deterrent differentiation reduces but does not remove substitution; under utilization controls net price is the key decision lever.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician and patient influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePhysician and patient influence is constrained: prescribers prioritize efficacy and safety but payer rules and prior authorization limit choices, so utilization of Collegium products is driven more by reimbursement policies than individual preference. Patients in insured channels have limited direct bargaining power; formulary placement and quantity limits shape demand. Education and real-world outcomes data still sway uptake within those constraints.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrescribers: clinical efficacy vs payer constraints\u003c\/li\u003e\n\u003cli\u003ePatients: low bargaining power in insured markets\u003c\/li\u003e\n\u003cli\u003ePayer controls: prior auth and quantity limits dominate\u003c\/li\u003e\n\u003cli\u003eLevers: education and outcomes data to boost adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompliance and risk scrutiny\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePayers and health systems increasingly scrutinize opioid risk, diversion, and patient outcomes; FDA in 2024 maintains opioid REMS and CDC data show opioid-involved overdose deaths exceeded 100,000 in 2022, driving tighter controls that reduce volumes and raise evidence bars. Real-world data and documented REMS adherence are now common access prerequisites, giving buyers non-price leverage to demand demonstrated value.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eREMS mandatory (FDA 2024)\u003c\/li\u003e\n\u003cli\u003eOverdose deaths \u0026gt;100,000 (CDC 2022)\u003c\/li\u003e\n\u003cli\u003eRWD required for formulary access\u003c\/li\u003e\n\u003cli\u003eNon-price leverage: outcomes, diversion controls\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBMs control \u003cstrong\u003e78–80%\u003c\/strong\u003e of US Rx; rebates squeeze margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge PBMs\/insurers control ~78–80% of U.S. prescription routing, extracting rebates commonly \u0026gt;30% and steering formulary\/prior auth decisions. Top-three wholesalers account for ~85% of distribution, using chargebacks and fees that compress margins. Prescriber choice is limited by payer rules; opioid prescriptions are ~50% below peak and FDA REMS plus \u0026gt;100,000 overdose deaths (2022) raise evidence\/access barriers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM market share\u003c\/td\u003e\n\u003ctd\u003e78–80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical rebate\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop3 wholesalers\u003c\/td\u003e\n\u003ctd\u003e~85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpioid Rx decline\u003c\/td\u003e\n\u003ctd\u003e~50% vs peak\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverdose deaths\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100,000 (2022)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eREMS\u003c\/td\u003e\n\u003ctd\u003eMandatory (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eCollegium Pharmaceutical Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Collegium Pharmaceutical Porter’s Five Forces analysis you'll receive immediately after purchase—no surprises or placeholders. The document is professionally written, fully formatted, and ready for download and use the moment you buy. You're viewing the final deliverable; instant access follows payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56163310600569,"sku":"collegiumpharma-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/collegiumpharma-five-forces-analysis.png?v=1762717136","url":"https:\/\/portersfiveforce.com\/products\/collegiumpharma-five-forces-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}